# Immunogenicity-Related Considerations for Low Molecular Weight Heparin Guidance for Industry - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/immunogenicity-related-considerations-for-low-molecular-weight-heparin-guidance-for-industry/3f5ab3c9-bcf6-4c53-bf06-2133ec436dd8

> FDA guidance document: Immunogenicity-Related Considerations for Low Molecular Weight Heparin Guidance for Industry. Issue date: February 18, 2016. Get complete insights and analysis.

---

## Details

- Title: Immunogenicity-Related Considerations for Low Molecular Weight Heparin Guidance for Industry
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2016-02-18
- Last Changed: 2019-05-31

## Related Documents

- [Botanical Drug Development: Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/botanical-drug-development-guidance-for-industry/bec78068-96c3-424e-b070-7b4ecfcfc8bf)
- [Quality Attribute Considerations for Chewable Tablets Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/quality-attribute-considerations-for-chewable-tablets-guidance-for-industry/04e1f98a-29f4-4cc9-a0ab-4017b9877ce9)
- [Regulatory Classification of Pharmaceutical Co-Crystals](https://www.globalkeysolutions.net/guidances/guidance-document/regulatory-classification-of-pharmaceutical-co-crystals/b288c932-6da7-45b6-b036-5876350c1f0f)